Clinical Trials Logo

Intracerebral Hemorrhage clinical trials

View clinical trials related to Intracerebral Hemorrhage.

Filter by:

NCT ID: NCT00526214 Completed - Clinical trials for Intracerebral Hemorrhage

Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study

ACE-ICH
Start date: October 2007
Phase: N/A
Study type: Interventional

Primary: Change of volume of perihematomal edema as assessed by brain CT. Secondary: The change of ICH volume between the initial and the follow-up CT scans The neurological status at 90 day using E-GOS and mRS. The cumulative incidence of major and minor adverse events that occurred during and after hospitalization until the end of the study

NCT ID: NCT00490464 Completed - Clinical trials for Subarachnoid Hemorrhage

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

Start date: June 2004
Phase: N/A
Study type: Observational

The purpose of this research is to explore ways to improve and simplify control of blood pressure in patients with SAH or ICH. This research will be done by comparing tow different medications that are routinely used to help control blood pressure. None of the medications used in this study nor any procedures performed are experimental.

NCT ID: NCT00415610 Completed - Stroke Clinical Trials

Antihypertensive Treatment in Acute Cerebral Hemorrhage

ATACH
Start date: July 2005
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to evaluate the safety and effectiveness of lowering blood pressure using nicardipine in persons with acute hypertension associated with intracerebral hemorrhage.

NCT ID: NCT00364559 Completed - Stroke Clinical Trials

Effect of Rosuvastatin in Intracerebral Hemorrhage

Start date: August 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether rosuvastatin is effective in the management of acute phase of intracerebral hemorrhage and if it impact outcome by NIHSS.

NCT ID: NCT00224770 Completed - Clinical trials for Intracerebral Hemorrhage

Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation

MISTIE
Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of using a combination of minimally invasive surgery and clot lysis with rt-PA to remove intracerebral hemorrhage (ICH). The ICES arm of the trial will determine the safety of endoscopic surgery to remove ICH. All MISTIE intention to treat subjects represent the hypothesized test group. The ICES cohort is to be analyzed separately.

NCT ID: NCT00222625 Recruiting - Clinical trials for Intracerebral Hemorrhage

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelets agents

NCT ID: NCT00128050 Completed - Clinical trials for Intracerebral Hemorrhage

Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)

PRE-SICH
Start date: January 2005
Phase: Phase 2
Study type: Interventional

Although the role of surgical treatment is still controversial, surgical evacuation of intracerebral hematoma is a frequent practice. Rebleeding is a frequent complication in patients submitted to hematoma evacuation. It has been reported that smaller postoperative volume of hematoma is associated with a better outcome. The investigators hypothesize that the administration of Factor VIIa (Eptacog alfa) immediately after surgical evacuation of the hematoma can reduce postoperative rebleeding. Aims of the Study: This study will investigate: 1. The efficacy of Eptacog alfa in preventing or reducing rebleeding after surgery for spontaneous supratentorial ICH; and 2. The safety of product administration

NCT ID: NCT00075959 Completed - Clinical trials for Intracerebral Hemorrhage

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Start date: August 2004
Phase: Phase 2
Study type: Interventional

This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.